Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Yujie Ren in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Xue Han in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Yujiang Li in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Key Laboratory of TCM Syndrome and Treatment of Yingbing (Thyroid Disease) of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Guofang Chen in
Google Scholar
PubMed
Search for other papers by Lin Jiang in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Key Laboratory of TCM Syndrome and Treatment of Yingbing (Thyroid Disease) of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Chao Liu in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Shuhang Xu in
Google Scholar
PubMed
bilateral vocal cord movement examined by laryngoscopy. Hypoparathyroidism was diagnosed by a parathyroid hormone level < 15 pg/mL at 24 h postoperatively. Permanent recurrent laryngeal nerve injury and hypoparathyroidism were defined as no recovery of the
DFBMC, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
Search for other papers by Carolina Inda in
Google Scholar
PubMed
Search for other papers by Natalia G Armando in
Google Scholar
PubMed
Search for other papers by Paula A dos Santos Claro in
Google Scholar
PubMed
DFBMC, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
Search for other papers by Susana Silberstein in
Google Scholar
PubMed
pyramidal neurons of the hippocampus ( 127 , 128 ). For GPCRs such as parathyroid hormone receptor (PTHR1) or β2-adrenergic receptor (β2AR) the involvement of Gβγ complex on signaling has been studied in detail ( 129 , 130 ), leading to the discovery of
Search for other papers by Julia Kubiak in
Google Scholar
PubMed
Search for other papers by Per Medbøe Thorsby in
Google Scholar
PubMed
Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
Search for other papers by Elena Kamycheva in
Google Scholar
PubMed
Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
Search for other papers by Rolf Jorde in
Google Scholar
PubMed
Mannheim and a modified Jaffe reaction (Roche Hitachi 911) was used for measurement of serum creatinine. Intact parathyroid hormone (PTH) was analysed with an electrochemiluminescence immunoassay (ECLIA) using an automated clinical chemistry analyser (Cobas
Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, INSERM, UMRS1138, Paris, France
Search for other papers by Jean-Philippe Bertocchio in
Google Scholar
PubMed
Search for other papers by Natalie Grosset in
Google Scholar
PubMed
Search for other papers by Lionel Groussin in
Google Scholar
PubMed
Search for other papers by Peter Kamenický in
Google Scholar
PubMed
Search for other papers by Fabrice Larceneux in
Google Scholar
PubMed
Search for other papers by Anne Lienhardt-Roussie in
Google Scholar
PubMed
Université Paris-Saclay, Inserm U1185, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Service d’Endocrinologie et Diabète de l’Enfant, Centre de Référence des Maladies Rares du Calcium et du Phosphore et Filière de Santé Maladies Rares OSCAR, Hôpital Bicêtre Paris Saclay, Le Kremlin-Bicêtre, France
Search for other papers by Agnès Linglart in
Google Scholar
PubMed
Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
Assistance Publique-Hôpitaux de Paris, Institut Necker-Enfants Malades, INSERM U1151 – CNRS UMR 8253, Paris, France
Search for other papers by Gérard Maruani in
Google Scholar
PubMed
Association Francophone de Chirurgie Endocrinienne (AFCE), France
Search for other papers by Eric Mirallie in
Google Scholar
PubMed
Search for other papers by François Pattou in
Google Scholar
PubMed
Search for other papers by Riyad N H Seervai in
Google Scholar
PubMed
Search for other papers by Coralie Sido in
Google Scholar
PubMed
Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Biochimie et Génétique Moléculaires, Paris, France
INSERM, U1169, Université Paris Sud, Hôpital Bicêtre, Le Kremlin Bicêtre, France
Search for other papers by Caroline Silve in
Google Scholar
PubMed
INSERM, U1418, CIC-EC, Hôpital Européen Georges Pompidou, Paris, France
Search for other papers by Aurélie Vilfaillot in
Google Scholar
PubMed
Search for other papers by Antoine Tabarin in
Google Scholar
PubMed
Search for other papers by Marie-Christine Vantyghem in
Google Scholar
PubMed
Centre de Référence des Maladies Rares du Calcium et du Phosphore Filière de Santé Maladies Rares OSCAR, Paris, France
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, INSERM, UMRS1138, Paris, France
CNRS, ERL8228, Paris, France
Search for other papers by Pascal Houillier in
Google Scholar
PubMed
Search for other papers by the investigators of the Épi-Hypo study in
Google Scholar
PubMed
Introduction Hypoparathyroidism is a rare condition caused by undetectable or inappropriately low secretion of parathyroid hormone (PTH) that is insufficient for maintaining the plasma calcium concentration (PCa) within the normal range ( 1
Search for other papers by Athanasios Zervas in
Google Scholar
PubMed
National and Kapodistrian University of Athens Medical School, ‘Aghia Sophia’ Children’s Hospital, Athens, Greece
Search for other papers by George Chrousos in
Google Scholar
PubMed
Search for other papers by Sarantis Livadas in
Google Scholar
PubMed
. ( https://doi.org/10.1210/jc.2010-0498 ) 62 Kanatani M Sugimoto T Kaji H Ikeda K Chihara K Skeletal responsiveness to parathyroid hormone in pseudohypoparathyroidism . European Journal of Endocrinology 2001 144 263 – 269 . ( https
Search for other papers by Yi Chen in
Google Scholar
PubMed
Search for other papers by Wen Zhang in
Google Scholar
PubMed
Search for other papers by Chi Chen in
Google Scholar
PubMed
Search for other papers by Yuying Wang in
Google Scholar
PubMed
Search for other papers by Ningjian Wang in
Google Scholar
PubMed
Search for other papers by Yingli Lu in
Google Scholar
PubMed
effects of metformin and thiazolidinedione on bone metabolism were considered, the effects of multiple antidiabetic drugs on bone metabolism were not discussed in this study. Fourthly, calcium concentration, parathyroid hormone concentration and BMD were
Search for other papers by Julia Herteux in
Google Scholar
PubMed
Search for other papers by Simon Johannes Geiger in
Google Scholar
PubMed
Search for other papers by Christina Starchl in
Google Scholar
PubMed
Search for other papers by Johanna Windisch in
Google Scholar
PubMed
Search for other papers by Theresa Lerchl in
Google Scholar
PubMed
Search for other papers by Adelina Tmava-Berisha in
Google Scholar
PubMed
Search for other papers by Gerit Wünsch in
Google Scholar
PubMed
Search for other papers by Kathrin Eller in
Google Scholar
PubMed
Search for other papers by Astrid Fahrleitner-Pammer in
Google Scholar
PubMed
Search for other papers by Karin Amrein in
Google Scholar
PubMed
following criteria: the documented diagnosis, parathyroid hormone (PTH) levels <30 pg/mL, hypo-/normocalcemia, with/without ongoing therapy, at least 2 recorded low calcium values at least 6 months apart. We included patients of all age groups. Subsequently
Search for other papers by Debra M Gordon in
Google Scholar
PubMed
Search for other papers by Pablo Beckers in
Google Scholar
PubMed
Search for other papers by Emilie Castermans in
Google Scholar
PubMed
Search for other papers by Sebastian J C M M Neggers in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Vincent Bours in
Google Scholar
PubMed
Search for other papers by Patrick Petrossians in
Google Scholar
PubMed
Search for other papers by Vinciane Dideberg in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
particularly true in the case of pheochromocytomas and paragangliomas (PPGL) ( 1 ). These neuroendocrine tumors produce symptoms due to direct tumor effects and the synthesis and release of bioactive amines, neurotransmitters, and hormones; about 20 new
Search for other papers by Ann-Kristin Picke in
Google Scholar
PubMed
Search for other papers by Graeme Campbell in
Google Scholar
PubMed
Division of Bone and Mineral Diseases, Washington University in St Louis, St Louis, Missouri, USA
Search for other papers by Nicola Napoli in
Google Scholar
PubMed
Search for other papers by Lorenz C Hofbauer in
Google Scholar
PubMed
Search for other papers by Martina Rauner in
Google Scholar
PubMed
density; PTH, parathyroid hormone; SGLT2, sodium-glucose cotransporter 2. Effects of antidiabetic treatments on bone Metformin Metformin is taken orally and decreases production of hepatic glucose via inhibition of mitochondrial
Search for other papers by S Westra in
Google Scholar
PubMed
Search for other papers by Y H M Krul-Poel in
Google Scholar
PubMed
Search for other papers by H J van Wijland in
Google Scholar
PubMed
Search for other papers by M M ter Wee in
Google Scholar
PubMed
Search for other papers by F Stam in
Google Scholar
PubMed
Search for other papers by P Lips in
Google Scholar
PubMed
Search for other papers by F Pouwer in
Google Scholar
PubMed
Search for other papers by S Simsek in
Google Scholar
PubMed
numbers (%). * Including retinopathy, nephropathy and neuropathy. † Maximum dose of 400 IU vitamin D supplement daily before the start of the trial. 25(OH)D, 25 hydroxyvitamin D; PTH, parathyroid hormone; SU derivatives, sulphonylurea